Qiagen Forms Molecular Dx Joint Venture in Singapore

Dec 03, 2007

NEW YORK (GenomeWeb News) – Qiagen is starting a joint venture in Singapore with Bio*One Capital, a biomedical investment management company based in that country, that will develop molecular diagnostic assays for genetic and infectious diseases, the firms said today.

The venture, called Dx Assays, should be operational by early 2008 and will be staffed with over 30 researchers, the companies said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Faster Profiles

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

Standards Needed

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

Conflict Search

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

This Week in Science

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.

Main menu